These in vivo results, coupled with our in vitro findings, demonstrate that TYK2 inhibitor alleviates inflammation in KCs predominantly through the AKT‐SP1‐NGFR‐AP1 signalling pathway, thereby effectively reducing psoriasis‐like skin inflammation (Figure 6N). Here, JUND is linked to psoriasis.